Epidemiology of psoriatic arthritis in the population of the United States - 21/08/11
, Dafna D. Gladman, MD b, Philip J. Mease, MD c, Nana Smith, BA a, David J. Margolis, MD, PhD a, Tamar Nijsten, MD, PhD d, Robert S. Stern, MD e, Steven R. Feldman, MD, PhD f, Tara Rolstad, MBA g
Correspondence to: Joel M. Gelfand MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 3600 Spruce St, 2 Maloney Building, Philadelphia, PA 19104.Philadelphia, Pennsylvania; Toronto, Ontario, Canada; Seattle, Washington; Edegem, Belgium; Boston, Massachusetts; Wake Forest, North Carolina; and Portland, Oregon
Abstract |
Background |
Estimates of the prevalence of psoriatic arthritis vary widely and are usually not determined by population-based studies.
Objectives |
We sought to determine the prevalence of psoriatic arthritis and the impact of the disease on quality of life in the US population.
Methods |
Patients were selected randomly from the US population and were interviewed by telephone. Cases were defined as patients who reported a physician diagnosis of psoriasis and psoriatic arthritis.
Results |
Interviews of 27,220 persons were conducted; 601 of the interviewees had psoriasis and 71 had psoriasis and psoriatic arthritis. The prevalence of psoriatic arthritis was 0.25% (95% confidence interval [CI]: 0.18%, 0.31%). The prevalence of psoriatic arthritis among patients with psoriasis was 11% (95% CI: 9%, 14%) and varied substantially based on self-reporting of the extent of skin involvement with psoriasis. Thirty-nine percent of patients with psoriatic arthritis indicated that it was a large problem in everyday life.
Limitations |
Psoriatic arthritis was classified on the basis of the patient's self-report.
Conclusion |
Psoriatic arthritis affects an estimated 520,000 patients in the US population, and many rate it as a large problem in everyday life. The prevalence varies widely based on the extent of skin involvement, which demonstrates the importance of performing broadly representative studies to measure the prevalence of psoriatic arthritis.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: NIAMS K23 AR051125-01 (JMG). The Psoriasis Foundation gratefully acknowledges Biogen, Amgen, and Wyeth for their unrestricted grant to help make the survey possible. The Psoriasis Foundation was solely responsible for all survey content and development. Conflicts of interest: None identified. |
|
| Reprints not available from the authors. |
Vol 53 - N° 4
P. 573.e1-573.e13 - octobre 2005 Retour au numéro
Article précédent
- American Board of Dermatology examination dates
- Pulse versus continuous terbinafine for onychomycosis: A randomized, double-blind, controlled trial
- Erin M. Warshaw, Debra D. Fett, Hanna E. Bloomfield, Joseph P. Grill, David B. Nelson, Vicente Quintero, Susan M. Carver, Gary R. Zielke, Frank A. Lederle
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?